Urinebased Molecular Testing versus Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer

Overview

About this study

The purpose of this study is to evaluate patient-reported preference for CxBladder Monitor compared to cystoscopy for patients on surveillance for NMIBC.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Male or female with a history of histologically confirmed stage 0 (Ta and/or CIS) nonmuscle invasive bladder cancer who have at least 9 months of disease-free survival from last recurrence.
Able to provide urine for testing and comply with study protocol.
Have an email address and be willing to complete surveys online.

Exclusion Criteria:

History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma).
Patients with predominant (> 50%) variant histology.
Patients with a history of upper tract and/or urethral cancer.
Patients with a history of T1 NMIBC.
Women who are pregnant.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 7/5//23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Mark Tyson, M.D., M.P.H.	Open for enrollment	Contact information: Cancer Center Clinical Trials Referral Office (855) 776-0015

Mayo Clinic Location

Status

Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mark Tyson, M.D., M.P.H.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Clinical Trials